Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 1;22(6):61.
doi: 10.1007/s11912-020-00918-7.

Molecular Landscape of Acute Myeloid Leukemia: Prognostic and Therapeutic Implications

Ludovica Marando  1   2 , Brian J P Huntly  3   4
Affiliations
Review

Molecular Landscape of Acute Myeloid Leukemia: Prognostic and Therapeutic Implications

Ludovica Marando et al. Curr Oncol Rep. .

Abstract

Purpose of review: The field of acute myeloid leukemia (AML) has been revolutionized in recent years by the advent of high-throughput techniques, such as next-generation sequencing. In this review, we will discuss some of the recently identified mutations that have defined a new molecular landscape in this disease, as well as their prognostic, predictive, and therapeutic implications.

Recent findings: Recent studies have shown how many cases of AML evolve from a premalignant period of latency characterized by the accumulation of several mutations and the emergence of one or multiple dominant clones. The pattern of co-occurring mutations and cytogenetic abnormalities at diagnosis defines risk and can determine therapeutic approaches to induce remission. Besides the genetic landscape at diagnosis, the continued presence of particular gene mutations during or after treatment carries prognostic information that should further influence strategies to maintain remission in the long term. The recent progress made in AML research is a seminal example of how basic science can translate into improving clinical practice. Our ability to characterize the genomic landscape of individual patients has not only improved our ability to diagnose and prognosticate but is also bringing the promise of precision medicine to fruition in the field.

Keywords: Clonal evolution; Genomics; Mutations; Preleukemia; Prognosis; Targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Ludovica Marando and Brian J. P. Huntly declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Timing of the identification of mutations associated with AML and evolution of therapeutic strategies. More widespread use of sequencing technologies has enriched the landscape of mutations that are associated with AML. An enhanced ability to diagnose and prognosticate is now translating into an increased understanding of therapeutic vulnerabilities and the development of new therapies. Between 2017 and 2018, the FDA has approved eight novel drugs for the treatment of AML and for the first time in almost 40 years, and AML patients can benefit from a more individualized treatment approach
See this image and copyright information in PMC

References

    1. Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127(1):29–41. doi: 10.1182/blood-2015-07-604496. - DOI - PMC - PubMed
    1. Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet. 1977;1(8010):549–550. doi: 10.1016/s0140-6736(77)91415-5. - DOI - PubMed
    1. Lindgren V, Rowley JD. Comparable complex rearrangements involving 8;21 and 9;22 translocations in leukaemia. Nature. 1977;266(5604):744–745. doi: 10.1038/266744a0. - DOI - PubMed
    1. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079–1089. doi: 10.1056/NEJMoa1112304. - DOI - PMC - PubMed
    1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405. 10.1182/blood-2016-03-643544. - PubMed